Immune-related adverse events in older adults receiving immune checkpoint inhibitors: a comprehensive analysis of the Food and Drug Administration Adverse Event Reporting System
Age and Ageing · 06.01.2025 · 54 (1)
DOI: 10.1093/ageing/afaf008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Age and Ageing, online erschienen am 30.01.2025. Verfasst von Buğra Han Esen und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Koç University, Rumelifeneri Yolu 34450 Sarıyer, Istanbul, Turkey. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Adverse Drug Reaction Reporting Systems, Neoplasms, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Immune checkpoint inhibitors (ICIs) have revolutionised cancer therapy, yet they carry a unique spectrum of immune-related adverse events (irAEs). Given the ageing global population and the underrepresentation of older adults in clinical trials for ICIs, we investigated the occurrence and characteristics of irAEs in older versus younger adults as well as among different age subsets within the older adult population.
Methods
We analysed the U.S. Food and Drug Administration Adverse Event Reporting System database reports from 2015 to 2023, focusing on ICIs. We categorised irAEs into 11 distinct types and performed descriptive and multivariate analyses to compare the prevalence and clinical characteristics of irAEs across different age groups, adjusting for potential confounding factors.
Results
Among 47 513 patients aged 18–100 reporting irAEs, the 65–74 and 75–84 age groups had significantly increased risks compared to 18–64 (OR 1.13, 95% CI [1.09–1.18]; 1.15 [1.1–1.21]). Cardiovascular irAEs rose with age, peaking at 75–84, while endocrine irAEs decreased. Hepatobiliary, gastrointestinal and ocular irAEs decreased with age, but renal and musculoskeletal irAEs increased, showing higher risks in older adults. Serious outcomes slightly decreased in the 85+ group, while the proportion of deaths increased with age.
Conclusion
We discuss the potential changes in the immune system contributing to the decreased prevalence of irAEs in the oldest age group. Additionally, conservative treatment approaches and underreporting of irAEs in older patients may influence these findings. Our findings highlight the need for personalised decision-making for ICI therapies, considering performance status and comorbidities rather than age alone.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Koç University, Rumelifeneri Yolu 34450 Sarıyer, Istanbul, Turkey.
- Department of Medical Oncology, Koç University Hospital, Davutpaşa Street 34010 Topkapı, Istanbul, Turkey.
- Department of Internal Medicine, Koç University Hospital, Davutpaşa Street 34010 Topkapı, Istanbul, Turkey.
- Division of Geriatrics, Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University, 34093 Fatih, Istanbul, Turkey.
ORCID-Profile: Buğra Han Esen, Sevval Nur Bektas, Umur Topcu, Bahadır Köylü, Fadime Buket Bayram Kuvvet, Gulistan Bahat
Zitieren
APA
Esen, B. H., Bektas, S. N., Topcu, U., Köylü, B., Kuvvet, F. B. B., Bahat, G., & Selçukbiricik, F. (2025). Immune-related adverse events in older adults receiving immune checkpoint inhibitors: a comprehensive analysis of the Food and Drug Administration Adverse Event Reporting System. Age and Ageing, 54(1). https://doi.org/10.1093/ageing/afaf008
Vancouver
Esen BH, Bektas SN, Topcu U, Köylü B, Kuvvet FBB, Bahat G, et al. Immune-related adverse events in older adults receiving immune checkpoint inhibitors: a comprehensive analysis of the Food and Drug Administration Adverse Event Reporting System. Age and Ageing. 2025;54(1). doi:10.1093/ageing/afaf008
BibTeX
@article{Esen2025,
author = {Esen, Buğra Han and Bektas, Sevval Nur and Topcu, Umur and Köylü, Bahadır and Kuvvet, Fadime Buket Bayram and Bahat, Gulistan and Selçukbiricik, Fatih},
title = {Immune-related adverse events in older adults receiving immune checkpoint inhibitors: a comprehensive analysis of the Food and Drug Administration Adverse Event Reporting System},
journal = {Age and Ageing},
year = {2025},
volume = {54},
number = {1},
doi = {10.1093/ageing/afaf008}
}
EUVIMED